TY - JOUR
T1 - Rituximab immunotherapy for ocular adnexal lymphoma
T2 - Clinicopathologic correlation with 5-year follow-up
AU - Sokol, Jason A.
AU - Landau, Leon
AU - Lauer, Simeon A.
PY - 2009/7
Y1 - 2009/7
N2 - Two patients with primary ocular adnexal mucosaassociated lymphoid tumor lymphoma were treated with rituximab immunotherapy. One patient had refused radiotherapy. The other had bilateral ischemic retinopathy, a relative contraindication to radiotherapy. Biopsies were performed 6 months after treatment. One patient had complete resolution of local disease, and the other had a partial response, remaining stable without signs of progression. During the 5 years of clinical follow-up, there was no evidence of systemic disease in either patient. Rituximab immunotherapy is an alternative to regional radiotherapy for ocular adnexal mucosa-associated lymphoid tumor lymphoma.
AB - Two patients with primary ocular adnexal mucosaassociated lymphoid tumor lymphoma were treated with rituximab immunotherapy. One patient had refused radiotherapy. The other had bilateral ischemic retinopathy, a relative contraindication to radiotherapy. Biopsies were performed 6 months after treatment. One patient had complete resolution of local disease, and the other had a partial response, remaining stable without signs of progression. During the 5 years of clinical follow-up, there was no evidence of systemic disease in either patient. Rituximab immunotherapy is an alternative to regional radiotherapy for ocular adnexal mucosa-associated lymphoid tumor lymphoma.
UR - http://www.scopus.com/inward/record.url?scp=69449106148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69449106148&partnerID=8YFLogxK
U2 - 10.1097/IOP.0b013e3181aadbb1
DO - 10.1097/IOP.0b013e3181aadbb1
M3 - Article
C2 - 19617799
AN - SCOPUS:69449106148
SN - 0740-9303
VL - 25
SP - 322
EP - 324
JO - Ophthalmic plastic and reconstructive surgery
JF - Ophthalmic plastic and reconstructive surgery
IS - 4
ER -